| Biomarker ID | 1095 |
| PMID | 23574937 |
| Year | 2013 |
| Biomarker | miR-16 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Downregulated in metastatic castration-resistant PCa (mCRPC) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- RNA binding; nucleus; nucleoplasm; protein-containing complex; ribonucleoprotein complex |
| Experiment | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) |
| Type of Biomarker | Prognostic |
| Cohort | 25 PCa patients with treatment-naive localized disease (localized PCa) and 25 patients with metastatic castration resistant PCa and a rising PSA (mCRPC patients) were chosen for the study |
| Senstivity | 24% |
| Specificity | 96% |
| AUC | 0.7160 [955 CI: 0.5708 - 0.8612] |
| Accuracy | NA |
| Level Of Significance | p < 0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-16 |